Sign up to save your podcasts
Or
Share 314: JD Vance's biotech ties, Cassava resignations, and insulin shortages
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
314: JD Vance's biotech ties, Cassava resignations, and insulin shortages
Our Washington correspondent Sarah Owermohle joins us to talk about how JD Vance, Donald Trump's newly announced running mate, could influence health policy if Trump wins the election. We also discuss the latest news in the biopharma industry, including the latest developments in the ongoing controversy surrounding Cassava’s Alzheimer’s drug, shortages of insulin as Novo Nordisk and Eli Lilly turn their focus toward GLP-1 drugs, and a shakeup in leadership at Gilead.
View all episodes
By STAT
4.5
320320 ratings
Our Washington correspondent Sarah Owermohle joins us to talk about how JD Vance, Donald Trump's newly announced running mate, could influence health policy if Trump wins the election. We also discuss the latest news in the biopharma industry, including the latest developments in the ongoing controversy surrounding Cassava’s Alzheimer’s drug, shortages of insulin as Novo Nordisk and Eli Lilly turn their focus toward GLP-1 drugs, and a shakeup in leadership at Gilead.
More shows like The Readout Loud
View all
Odd Lots
1,993 Listeners
Nature Podcast
756 Listeners
The a16z Show
1,105 Listeners
Science Magazine Podcast
818 Listeners
What the Health? From KFF Health News
498 Listeners
The Long Run with Luke Timmerman
125 Listeners
The Journal.
6,097 Listeners
Biotech 2050 Podcast
61 Listeners
Business Of Biotech
85 Listeners
BioCentury This Week
34 Listeners
Hard Fork
5,576 Listeners
First Opinion Podcast
55 Listeners
Biotech Hangout
21 Listeners
Money Stuff: The Podcast
403 Listeners
The Top Line
17 Listeners
The BioCentury Show
11 Listeners